Activation of histamine H3 receptors in human nasal mucosa inhibits sympathetic vasoconstriction

European Journal of Pharmacology

Volumn 484, Issue 1, 2004, Pages 83-89

  Varty, LoriAnn M ^a   Gustafson, Eric ^a   Laverty, Maureen ^a   Hey, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Histamine H3 receptor; Human; Nasal mucosa; Sympathetic; Taqman

Indexed keywords

CHLORPHENIRAMINE; CIMETIDINE; CLOBENPROPIT; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; MESSENGER RNA; METHYLHISTAMINE; NORADRENALIN; PRAZOSIN; TETRODOTOXIN; UNCLASSIFIED DRUG; VASODILATOR AGENT; YOHIMBINE; ANTIHISTAMINIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BLOOD VESSEL TONE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ELECTROSTIMULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MUSCLE CONTRACTILITY; NORADRENALIN RELEASE; NOSE MUCOSA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SYMPATHETIC TONE; VASOCONSTRICTION; VASODILATATION; ADRENERGIC NERVE; COMPARATIVE STUDY; IN VITRO STUDY; METABOLISM; METHODOLOGY; MIDDLE AGED; NERVE CELL INHIBITION; PHYSIOLOGY;

ADOLESCENT; ADRENERGIC FIBERS; ADULT; ELECTRIC STIMULATION; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; NASAL MUCOSA; NEURAL INHIBITION; RECEPTORS, HISTAMINE H3; VASOCONSTRICTION;

EID: 0347948452     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.10.051     Document Type: Article

References (24)

1. Baraniuk J.N. Mechanisms of Rhinitis. Allergy Asthma Proc. 19:1998;343-346.
2. 2-adrenergic dysfunction in canine myocardium. Cardiovasc. Res. 56:2002;225-234.
3. Christodoulopoulos P., Cameron L., Durham S., Hamid Q. Molecular pathology of allergic disease II: Upper airway disease. J. Allergy Clin. Immunol. Mol. Mech. Allergy Clin. Immunol. 105:2000;211-223.
4. Corey J.P., Houser S.M., Ng B.A. Nasal congestion: review of its etiology, evaluation and treatment. Ear Nose Throat. 79:2000;690-693.
5. 3 receptors inhibit cholinergic neurotransmission. J. Pharmacol. Exp. Ther. 258:1991;325-331.
6. 2-adrenoceptors. Eur. J. Pharmacol. 102:1984;261-267.
7. 3 receptors. Can. J. Physiol. Pharm. 73:1995;558-564.
8. 3-receptors. Br. J. Pharmacol. 107:1992;347-351.
9. 3 receptor agonist Sch 50971. Arzneim.-Forsch. 48:1998;881-888.
10. Howarth P.H. The cellular basis for allergic rhinitis. Allergy. 50:1995;6-10.
11. 3-receptors in the human heart. Circ. Res. 77:1995;206-210.
12. Kaliner M.A. The mediators of the early and late phases of allergic rhinitis. Adv. Prostaglandin Thromboxane Leukotriene Res. 22:1994;271-278.
13. 3 receptors produces presynaptic inhibition of neurally evoked cat nictitating membrane responses in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 346:1992;208-212.
14. 3 activation depresses cardiac function in experimental sepsis. J. Appl. Physiol. 85(5):1998;1693-1701.
15. 3-receptors in the guinea pig vas deferens. Methods Find. Exp. Clin. Pharmacol. 16:1994;185-189.
16. 3 receptor mediated decrease in basal vascular resistance in guinea pigs. Br. J. Pharmacol. 110:1993;553-558.
17. 3-antagonists. Prog. Respir. Res. 31:2001;133-136.
18. 3 blockade produces nasal decongestion in an experimental model of nasal congestion. Am. J. Rhinol. 13:1999;391-399.
19. 3-receptor antagonist N-(3,5-Dichlorophenyl)-[[4-(1H- imidazol-4-ylmethyl]-urea (SCH 79687). J. Pharmacol. Exp. Ther. 305:2003;1037-1044.
20. 3 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 346:1992;46-50.
21. 3 receptors in human saphenous vein and guinea pig ileum. Eur. J. Pharmacol. 366:1999;73-78.
22. 3 receptor activation inhibits neurogenic sympathetic vasoconstriction in porcine nasal mucosa. Eur. J. Pharmacol. 452:2002;339-345.
23. Widdicombe J. Microvascular anatomy of the nose. Allergy. 52(40):1997;7-11.
24. 3 receptors inhibits renal noradrenergic neurotransmission in anesthetized dogs. Am. J. Physiol., Regul. Integr. Comp. Physiol. 280:2001;R1450-R1456.